Relay Therapeutics Reports Promising Interim Data for RLY-2608 in 2L PI3Kα-Mutated Metastatic Breast Cancer
Relay Therapeutics reports positive interim data for RLY-2608 in metastatic breast cancer, supporting a pivotal study in 2025.Quiver AI SummaryRelay Therapeutics, Inc. has announced updated interim clinical...
Relay Therapeutics to Present Updated Clinical Data for RLY-2608 at San Antonio Breast Cancer Symposium
Relay Therapeutics will present updated clinical data for RLY-2608 in advanced breast cancer at the San Antonio Symposium.Quiver AI SummaryRelay Therapeutics, a clinical-stage precision medicine company,...
Relay Therapeutics and Elevar Therapeutics Announce Global Licensing Agreement for Lirafugratinib, a Potential Best-in-Class FGFR2 Inhibitor
Elevar Therapeutics secures global rights to develop lirafugratinib, a promising FGFR2 inhibitor, with potential milestone payments for Relay Therapeutics.Quiver AI SummaryRelay Therapeutics and Elevar...
Why Relay Therapeutics Plummeted by Nearly 14% Today
Investors weren't happy with the company's latest effort at capital-raising.